Latest Breaking News On - High containment respiratory virus group - Page 1 : comparemela.com

Theralase Technologies Inc.: Theralase Commences Collaborative Research with National Microbiology Laboratory for Development of Coronavirus Vaccine ® Technologies Inc. ( TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds ( PDC ) and their associated drug formulations to safely and effectively destroy various cancers, bacteria and viruses, announced today that it has executed a Collaborative Research Agreement ( CRA ) with the National Microbiology Laboratory, Public Health Agency of Canada ( PHAC ) for the research and development of a Canadian-based SARS-CoV-2 ( COVID-19 ) vaccine. Under the terms of the agreement, Theralase ® and PHAC are collaborating on the development and optimization of a COVID-19 vaccine by treating the SARS-CoV-2 virus grown on cell lines with Theralase

Darwyn kobasaArkady mandelKristina hacheyKevin coombsWorld health organizationCollaborative research agreementUniversity of manitobaHigh containment respiratory virus groupSafety laboratoryDepartment of medical microbiology at university manitobaTechnologies incPublic health agency of canadaNational microbiology laboratoryVenture exchangeRegulation services providerTheralase technologies inc